These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11377136)

  • 1. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.
    de Luis DA; Bachiller P; Aller R
    Nutrition; 2001 May; 17(5):414-5. PubMed ID: 11377136
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate.
    Caramelli B; de Bernoche CY; Sartori AM; Sposito AC; Santos RD; Monachini MC; Strabelli T; Uip D
    Braz J Infect Dis; 2001 Dec; 5(6):332-8. PubMed ID: 11980596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reversibility of severe hyperlipemia secondary to indinavir with micronized phenofibrate].
    de Luis DA; Aller R; Rachiller P; Ignacio Tortosa J
    Med Clin (Barc); 1999 Nov; 113(18):716-7. PubMed ID: 10650577
    [No Abstract]   [Full Text] [Related]  

  • 4. Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
    de Luis DA; Bachiller P; Aller R; Eiros Bouza J; Izaola O
    Nutrition; 2003 Oct; 19(10):903-4. PubMed ID: 14559329
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on fenofibrate.
    Brown WV
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():31-40. PubMed ID: 3134383
    [No Abstract]   [Full Text] [Related]  

  • 7. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities.
    Thomas JC; Lopes-Virella MF; Del Bene VE; Cerveny JD; Taylor KB; McWhorter LS; Bultemeier NC
    Pharmacotherapy; 2000 Jun; 20(6):727-34. PubMed ID: 10853629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
    Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
    Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
    Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
    Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
    Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M
    Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
    Hirsch HH; Battegay M
    Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidemia associated with protease inhibitor therapy.
    Echevarria KL; Hardin TC; Smith JA
    Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates.
    Hegele RA; Pollex RL
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1224-7. PubMed ID: 17522394
    [No Abstract]   [Full Text] [Related]  

  • 17. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.
    Sebestjen M; Zegura B; Keber I
    J Intern Med; 2002 Jan; 251(1):77-85. PubMed ID: 11851868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
    Steinmetz J; Morin C; Panek E; Siest G; Drouin P
    Clin Chim Acta; 1981 Apr; 112(1):43=53. PubMed ID: 6113065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study.
    Calza L; Colangeli V; Manfredi R; Legnani G; Tampellini L; Pocaterra D; Chiodo F
    AIDS; 2005 Jul; 19(10):1103-5. PubMed ID: 15958843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.